(Reuters) -Novo Nordisk said on Monday it has become aware of several hundred units of counterfeit versions of its diabetes drug Ozempic being distributed outside its authorized supply chain in the United States.
The U.S. Food and Drug Administration was notified on April 3 about the counterfeit products and it seized them on April 9.
The FDA and Novo Nordisk are testing the seized products and do not yet have information about the identity, quality or safety of these drugs, the health regulator said.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber and Shilpi Majumdar)
Brought to you by www.srnnews.com
